PapiM.Microangiopathic ulcers of the lower extremities: a daily challenge. Int J Low Extrem Wounds. 2006;5:76-77.
2.
PapiMPapiC.Vasculitic ulcers. Int J Low Extrem Wounds. 2016;15:6-16.
3.
KimpimäkiTHoutari-oravaRAntonenJVaalastiA.Increased incidence of cutaneous vasculitic ulcers: 30-years results from a population-based retrospective study. Acta Derm Venereol. 2017;97:653-654.
4.
MonariPMoroRMotoleseAet al. Epidemiology of pyoderma gangrenosum: results from an Italian prospective multicentre study [published online June 6, 2018]. Int Wound J.
5.
Martinez-MeraCFragaJCapusanTMet al. Vasculopathies, cutaneous necrosis and emergency in dermatology. G Ital Dermatol Venereol. 2017;152:615-637.
6.
PapiMDidonaBDe PitàOet al. Livedo vasculopathy vs small vessel cutaneous vasculitis: cytokine and platelet P-selectin studies. Arch Dermatol. 1998;134:447-452.
7.
ShanmugamVK.Vasculitic diseases and prothrombotic states contributing to delayed healing in chronic wounds. Curr Dermatol Rep. 2016;5:270-277.
8.
KirsnerRS.Biological agents for chronic wounds. Am J Clin Dermatol. 2010;11(suppl 1):23-25.
9.
AssmannGPfreundshuhMVoswinkelJ.Rituximab in patients with rheumatoid arthritis and vasculitis-associated cutaneous ulcers. Clin Exp Rheumatol. 2010;28(1suppl 57):81-83.
10.
SriramSSankaralingamRManiMTamilselvamTN.Autologous platelet rich plasma in the management of non-healing vasculitic ulcers. Int J Rheum Dis. 2016;19:1331-1336.
11.
LaroucheJSheoranSMaruyamaKMartinoMM.Immune regulation of skin wound healing: mechanisms and novel therapeutic targets. Adv Wound Care (New Rochelle). 2018;7:209-231.
12.
PatelFFitzmauriceSDuongCet al. Effective strategies for the management of pyoderma gangrenosum: a comprehensive review. Acta Derm Venereol. 2015;95:525-531.
13.
DissemondJAssenheimerBEngelsPet al. M.O.I.S.T.—a concept for the topical treatment of chronic wounds. J Dtsch Dermatol Ges. 2017;15:443-445.
